🔎 Trials Near Me

Home › Kanser sa Pantog

Pag-aaral pangklinika para sa Kanser sa Pantog na nagre-recruit sa U.S.

142 pag-aaral para sa Kanser sa Pantog ang nagre-recruit ng mga kalahok sa mga site sa buong Estados Unidos.

Mga lungsod na may pinakamaraming pag-aaral

Ayos sa estado

Mga pag-aaral na kamakailan lamang in-update

Opisyal na teksto ng pag-aaral (English)

DK222 Study at Hopkins

Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Set 29, 2026 · NCT07140315

A Clinical Study of Intismeran Autogene (V940) and BCG in People With Bladder Cancer (V940-011/INTerpath-011)

Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Set 28, 2026 · NCT06833073

Symbiotic-GU-06: A Study to Learn About PF-08634404 Alone or In Combination With Enfortumab Vedotin in Urothelial Cancer

Nagre-recruitPhase 1/2
Edad 18 pataas · Lahat ng kasarian · Na-update Set 28, 2026 · NCT07421700

A Study to Learn About the Study Medicine PF-08052667 in People With Bladder Cancer

Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Set 28, 2026 · NCT07206225

En-bloc Transurethral Resection of Bladder Tumor (En-bloc TURBT) Specimens Using a Redesigned Surgical Resectoscope Device

Nagre-recruitObservasyonal na pag-aaral
Edad 18 hanggang 120 · Lahat ng kasarian · Na-update Set 28, 2026 · NCT04235764

A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors

Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Set 28, 2026 · NCT07277413

A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors

Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Set 25, 2026 · NCT06172478

DESTINY-PANTUMOUR04

Nagre-recruitObservasyonal na pag-aaral
Edad 18 hanggang 130 · Lahat ng kasarian · Na-update Set 25, 2026 · NCT07124000

A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) to Treat Urothelial Cancer (MK-2870-031)

Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Set 25, 2026 · NCT07419295

Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing Tumors

Nagre-recruitPhase 1/2
Edad 18 hanggang 99 · Lahat ng kasarian · Na-update Set 22, 2026 · NCT06814496

A Study of Surgical Techniques During Cystectomy

Nagre-recruitPhase 3
Edad 21 pataas · Lahat ng kasarian · Na-update Set 22, 2026 · NCT06703476

A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract

Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Set 22, 2026 · NCT07218380

Prehabilitation in High-risk Oncologic Surgery

Nagre-recruit
Edad 18 pataas · Lahat ng kasarian · Na-update Set 21, 2026 · NCT07638410

Personalized Cancer Vaccine (PCV) Strategy in Patients With Solid Tumors and Molecular Residual Disease

Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Set 21, 2026 · NCT06529822

Enfortumab Vedotin, Pembrolizumab and Quemliclustat for the Treatment of Unresectable Locally Advanced and Metastatic Urothelial Cancer

Nagre-recruitPhase 1/2
Edad 18 pataas · Lahat ng kasarian · Na-update Set 17, 2026 · NCT07667335

Enfortumab Vedotin and Stereotactic Radiation for Localized, Cisplatin Ineligible Muscle Invasive Bladder Cancer

Nagre-recruitPhase 1/2
Edad 18 pataas · Lahat ng kasarian · Na-update Set 17, 2026 · NCT06394570

ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation

Nagre-recruitObservasyonal na pag-aaral
Edad 18 pataas · Lahat ng kasarian · Na-update Set 14, 2026 · NCT05059444

A Clinical Study of MK-3120 in People With Bladder Cancer (MK-3120-003)

Nagre-recruitPhase 1/2
Edad 18 pataas · Lahat ng kasarian · Na-update Set 11, 2026 · NCT07222488

Mula sa ClinicalTrials.gov, na-kuha noong Set 30, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.